BACKGROUND: There have been contradictory results regarding temporal changes in the antimicrobial resistance of Escherichia coli from tertiary care centres. Therefore, we performed a population-based investigation to examine in vitro antimicrobial resistance trends of E. coli bloodstream isolates. METHODS: In this retrospective population-based incidence study, we identified 461 unique patients with first episodes of E. coli bloodstream infection (BSI) from 1 January 1998 to 31 December 2007 through microbiology records at the two laboratories in Olmsted County, Minnesota. Logistic regression was used to examine temporal changes in antimicrobial resistance and Poisson regression for changes in incidence rates. RESULTS: The median age of patients with E. coli BSI was 69 years; 306 (66.4%) were female. The age-adjusted incidence rate of E. coli BSI per 100 000 person-years was 48.0 (95% CI: 42.5-53.4) in females and 34.0 (95% CI: 28.6-39.6) in males. The urinary tract was the most common primary source of infection (79.8%). During the study period, resistance rates of E. coli bloodstream isolates increased from 32% to 53% for ampicillin, from 23% to 45% for ampicillin/sulbactam, from 9% to 28% for trimethoprim/sulfamethoxazole and from 0% to 12% for ciprofloxacin. Resistance rates to carbapenems, cephalosporins and piperacillin/tazobactam remained low and stable. CONCLUSIONS: To our knowledge, this is the first population-based study on antimicrobial resistance trends of E. coli bloodstream isolates in the USA. We demonstrated linear trends of increasing resistance among these isolates to three different classes of antimicrobial over the past decade.
BACKGROUND: There have been contradictory results regarding temporal changes in the antimicrobial resistance of Escherichia coli from tertiary care centres. Therefore, we performed a population-based investigation to examine in vitro antimicrobial resistance trends of E. coli bloodstream isolates. METHODS: In this retrospective population-based incidence study, we identified 461 unique patients with first episodes of E. coli bloodstream infection (BSI) from 1 January 1998 to 31 December 2007 through microbiology records at the two laboratories in Olmsted County, Minnesota. Logistic regression was used to examine temporal changes in antimicrobial resistance and Poisson regression for changes in incidence rates. RESULTS: The median age of patients with E. coli BSI was 69 years; 306 (66.4%) were female. The age-adjusted incidence rate of E. coli BSI per 100 000 person-years was 48.0 (95% CI: 42.5-53.4) in females and 34.0 (95% CI: 28.6-39.6) in males. The urinary tract was the most common primary source of infection (79.8%). During the study period, resistance rates of E. coli bloodstream isolates increased from 32% to 53% for ampicillin, from 23% to 45% for ampicillin/sulbactam, from 9% to 28% for trimethoprim/sulfamethoxazole and from 0% to 12% for ciprofloxacin. Resistance rates to carbapenems, cephalosporins and piperacillin/tazobactam remained low and stable. CONCLUSIONS: To our knowledge, this is the first population-based study on antimicrobial resistance trends of E. coli bloodstream isolates in the USA. We demonstrated linear trends of increasing resistance among these isolates to three different classes of antimicrobial over the past decade.
Authors: Imad M Tleyjeh; James M Steckelberg; Hani S Murad; Nandan S Anavekar; Hassan M K Ghomrawi; Zaur Mirzoyev; Sherif E Moustafa; Tanya L Hoskin; Jayawant N Mandrekar; Walter R Wilson; Larry M Baddour Journal: JAMA Date: 2005-06-22 Impact factor: 56.272
Authors: Conan MacDougall; J Patrick Powell; Christopher K Johnson; Michael B Edmond; Ronald E Polk Journal: Clin Infect Dis Date: 2005-06-28 Impact factor: 9.079
Authors: Daniel Z Uslan; Sarah J Crane; James M Steckelberg; Franklin R Cockerill; Jennifer L St Sauver; Walter R Wilson; Larry M Baddour Journal: Arch Intern Med Date: 2007-04-23
Authors: Galo Peralta; M Blanca Sánchez; J Carlos Garrido; Inés De Benito; M Eliecer Cano; Luis Martínez-Martínez; M Pía Roiz Journal: J Antimicrob Chemother Date: 2007-07-20 Impact factor: 5.790
Authors: Majdi N Al-Hasan; John W Wilson; Brian D Lahr; Kristine M Thomsen; Jeanette E Eckel-Passow; Emily A Vetter; Imad M Tleyjeh; Larry M Baddour Journal: Antimicrob Agents Chemother Date: 2009-01-21 Impact factor: 5.191
Authors: Ahmed M Elshal; Ahmed M Atwa; Ahmed R El-Nahas; Mohamed A El-Ghar; Asaad Gaber; Essam Elsawy; Abdelwahab Hashem; Yasser Farag; Hashim Farg; Ali Elsorougy; Mohamed Fouda; Hossam Nabeeh; Ahmed Mosbah Journal: World J Urol Date: 2018-05-07 Impact factor: 4.226
Authors: Ansal Shah; Julie Ann Justo; P Brandon Bookstaver; Joseph Kohn; Helmut Albrecht; Majdi N Al-Hasan Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Arch G Mainous; Vanessa A Diaz; Eric M Matheson; Seth H Gregorie; William J Hueston Journal: Public Health Rep Date: 2011 May-Jun Impact factor: 2.792
Authors: Florian M E Wagenlehner; Adrian Pilatz; Przemyslaw Waliszewski; Wolfgang Weidner; Truls E Bjerklund Johansen Journal: Nat Rev Urol Date: 2014-01-14 Impact factor: 14.432
Authors: Elizabeth B Nimmich; P Brandon Bookstaver; Joseph Kohn; Julie Ann Justo; Katie L Hammer; Helmut Albrecht; Majdi N Al-Hasan Journal: Hosp Pharm Date: 2017-07-21
Authors: Edward Goldstein; Derek R MacFadden; Zeynal Karaca; Claudia A Steiner; Cecile Viboud; Marc Lipsitch Journal: Int J Antimicrob Agents Date: 2019-03-06 Impact factor: 5.283